Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?
Küçük Resim Yok
Tarih
2019
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wiley
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
[Abstract Not Available]
Açıklama
Anahtar Kelimeler
Omalizumab Versus, Spontaneous Urticaria, Specific Patient
Kaynak
Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
74
Sayı
Supplement: 106
Künye
Kocatürk, E., Bülbül Başkan, E., Engin, B. H., Özdemir, M. A., Küçük, Ö. S., Can, P. ... Atakan, N. (2019). Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment? Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) içinde (484-485. ss.). Lisbon, Portugal, June 01-05, 2019.
